{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_Display\ Name in Display Name (approximate match)
Status:
Other
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
US Previously Marketed
Source:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/ucm071835.htm laxative:bulk laxative alpha cellulose
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M016
(2023)
Source URL:
First approved in 2023
Source:
M016
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 358H
(2013)
Source URL:
First approved in 2013
Source:
21 CFR 358H
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 346
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 346
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2010)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
NCT01145560: Phase 2 Interventional Completed Severe Sepsis
(2010)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01483287: Early Phase 1 Interventional Completed Irritable Bowel Syndrome
(2011)
Source URL:
Class:
STRUCTURALLY DIVERSE
